[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343956-105":59,"doc-detail-343956-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","atezolizumab-plus-bevacizumab-and-chemotherapy-as-first-line-therapy-for-cervical-cancer-a-cost-effectiveness-analysis-in-the-us","Atezolizumab plus bevacizumab and chemotherapy as first-line therapy for cervical cancer: a cost-effectiveness analysis in the US","","Medication dominates treatment for advanced cancers, yet novel anticancer drugs can intensify disease-related financial hardship. This study assesses the cost-effectiveness of adding atezolizumab to standard therapy (atezolizumab plus bevacizumab [BC]) for metastatic, persistent, and recurrent cervical cancer from the perspective of US healthcare payers, aiming to support policy decisions and promote efficient healthcare resource use.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/atezolizumab-plus-bevacizumab-and-chemotherapy-as-first-line-therapy-for-cervical-cancer-a-cost-effectiveness-analysis-in-the-us/343956/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/atezolizumab-plus-bevacizumab-and-chemotherapy-as-first-line-therapy-for-cervical-cancer-a-cost-effectiveness-analysis-in-the-us/343956.png","ImageObject",300,407,{"name":92,"@type":93},"Seraphina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of the study?","Question",{"text":112,"@type":113},"To evaluate the cost-effectiveness of adding atezolizumab to standard therapy for metastatic, persistent, and recurrent cervical cancer from a US healthcare payer perspective.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was cost-effectiveness analyzed?",{"text":117,"@type":113},"A partitioned survival model with a 20-year lifetime horizon compared atezolizumab plus bevacizumab and chemotherapy (ABC) versus BC, using BEATcc trial efficacy and safety data plus cost and utility inputs from public sources and literature.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show about ABC vs BC?",{"text":121,"@type":113},"ABC showed poor cost-effectiveness at both 20 and 4.5 years, with ICER values above the $150,000/QALY willingness-to-pay threshold.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343956,1790794349,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","TYPE Original Research PUBLISHED 27 November 2024 DOI 10.3389/fimmu.2024.1481584  \nOPEN ACCESS  \nEDITED BY  \nChun-Wai Mai,  \nUCSI University, Malaysia  \nREVIEWED BY  \nSafaet Alam,  \nBangladesh Council of Scientiﬁc and Industrial Research (BCSIR), Bangladesh Donatien Kamdem Toukam, University of Cincinnati, United States Jiahao Li,  \nJinan University, China  \n*CORRESPONDENCE  \nYuanqing Huang  \n [383196814@qq.com](383196814@qq.com)  \n†These authors have contributed equally to this work  \nRECEIVED 16 August 2024  \nACCEPTED 12 November 2024  \nPUBLISHED 27 November 2024  \nCITATION  \nLin Y, Li C, Wang C, Chen J and Huang Y (2024) Atezolizumab plus bevacizumab  \nand chemotherapy as ﬁrst-line therapy for cervical cancer: a costeffectiveness analysis in the US.  \nFront. Immunol. 15:1481584 .  \ndoi: 10.3389/fimmu.2024.1481584  \nCOPYRIGHT  \n© 2024 Lin, Li, Wang, Chen and Huang. This isan open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nAtezolizumab plus bevacizumab and chemotherapy as ﬁrstline therapy for cervical cancer: a cost-effectiveness analysis in the US  \nYingtao Lin 1†, Cijuan Li 2†, Chang Wang 3, Jian Chen 4 and Yuanqing Huang 5*  \n1Clinical Medical Research Center, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China, 2 Department of Comprehensive Surgery, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, China, 3 Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China, 4 Department of Gynecological-Surgical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China, 5 Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, China  \nObjective: Medication is the predominant therapy for advanced cancers. However, the use of novel anticancer medications is a major contributor to disease-related ﬁnancial hardships. Recently, numerous countries have mandated the pharmacoeconomic assessments of novel oncological agents to mitigate patient ﬁnancial risks and optimize resource allocation. The present study evaluated the cost-effectiveness of adding atezolizumab to standard therapy (atezolizumab plus bevacizumab [BC]) for metastatic, persistent, andrecurrent cervical cancer from the perspective of US healthcare payers, with the aim of supporting policymaking and promoting the rational use of healthcare resources.  \nMethods: Using clinical efﬁcacy and safety data from the BEATcc clinical trial, in addition to cost and utility values from publicly available databases and published literature, a partitioned survival model over a 20-year lifetime horizon was developed to assess the cost-effectiveness of atezolizumab plus bevacizumab and chemotherapy (ABC) versus BC. The primary output of the model was the incremental cost-effectiveness ratio (ICER) and sensitivity analyses were performed to assess its robustness.  \nResults: At both 20 and 4 . 5 y of time horizon, ABC therapy showed poor costeffectiveness, with ICER of $193926.48/QALY and $168482.26/QALY, respectively, which were higher than the $150,000/QALY willingness-to-pay threshold. One-way sensitivity analysis showed that the price of atezolizumab had the most signiﬁcant impact on the model results. When the price of atezolizumab was reduced by 10%, ABC changed from being not costeffective to cost-effective (ICER","cbCaiqyJpiRjwcrh","https://ap.wps.com/l/cbCaiqyJpiRjwcrh","pdf",2893099,11,"English","# Objective\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What is the main goal of the study?\",\"answer\":\"To evaluate the cost-effectiveness of adding atezolizumab to standard therapy for metastatic, persistent, and recurrent cervical cancer from a US healthcare payer perspective.\"},{\"question\":\"How was cost-effectiveness analyzed?\",\"answer\":\"A partitioned survival model with a 20-year lifetime horizon compared atezolizumab plus bevacizumab and chemotherapy (ABC) versus BC, using BEATcc trial efficacy and safety data plus cost and utility inputs from public sources and literature.\"},{\"question\":\"What did the results show about ABC vs BC?\",\"answer\":\"ABC showed poor cost-effectiveness at both 20 and 4.5 years, with ICER values above the $150,000/QALY willingness-to-pay threshold.\"}]","Atezolizumab plus bevacizumab and chemotherapy as first-line therapy for cervical cancer: a cost-effectiveness analysis in the US | PDF",1790052610,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/706b0870768e1f9cf6c54eed35583372.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3cfe4971d969ad8f7142ab2dae80d695.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/900a65301aea2c89ebccf49d6392d3b8.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f5cea721ae6fc2fe5a7666381ef0d0c.webp",980,1385]